Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Heart Failure Reports
Published in: Current Heart Failure Reports 2/2010

Open Access 01-06-2010

Pharmacoepigenetics in Heart Failure

Authors: Irene Mateo Leach, Pim van der Harst, Rudolf A. de Boer

Published in: Current Heart Failure Reports | Issue 2/2010

Login to get access

Abstract

Epigenetics studies inheritable changes of genes and gene expression that do not concern DNA nucleotide variation. Such modifications include DNA methylation, several forms of histone modification, and microRNAs. From recent studies, we know not only that genetic changes account for heritable phenotypic variation, but that epigenetic changes also play an important role in the variation of predisposition to disease and to drug response. In this review, we discuss recent evidence of epigenetic changes that play an important role in the development of cardiac hypertrophy and heart failure and may dictate response to therapy.
Literature
1.
de Boer RA, van der Harst P, van Veldhuisen DJ, MP van den Berg: Pharmacogenetics in heart failure: promises and challenges. Expert Opin Pharmacother 2009, 10:1713–1725.CrossRefPubMed
2.
Wellcome Trust Case Control Consortium: Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007, 447:661–678.CrossRef
3.
Codd V, Mangino M, van der Harst P, et al.: Common variants near TERC are associated with mean telomere length. Nat Genet 2010, 42:197–199.CrossRefPubMed
4.
Newton-Cheh C, Johnson T, Gateva V, et al.: Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet 2009, 41:666–676.CrossRef
5.
6.
Margulies KB, Bednarik DP, Dries DL: Genomics, transcriptional profiling, and heart failure. J Am Coll Cardiol 2009, 53:1752–1759.CrossRefPubMed
7.
Szyf M: Toward a discipline of pharmacoepigenomics. Curr Pharmacogenomics 2004, 2:357–377.CrossRef
8.
Peedicadyl J: Pharmacoepigenetics and pharmacoepigenomics. Pharmacogenomics 2008, 9:1785–1786.CrossRef
9.
Ingelman-Sundberg M, Sima SC, Gomez A, Rodriguez-Antona C: Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Therapeut 2007, 116:496–526.CrossRef
10.
• Mano H: Epigenetic abnormalities in cardiac hypertrophy and heart failure. Environ Health Prev Med 2008, 13:25–29. This review offers a good overview of histone acetylation in relation to HF.CrossRefPubMed
11.
Bernstein BE, Meissner A, Lander ES: Genomic maps and comparative analysis of histone modifications in human and mouse. Cell 2005, 120:169–181.CrossRefPubMed
12.
Zhang CL, McKinsey TA, Chang S, et al.: Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 2002 110:479–488.CrossRefPubMed
13.
Trivedi CM, Luo Y, Yin Z, et al.: Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity. Nat Med 2007, 13:324–331.CrossRefPubMed
14.
15.
Peaston AE, Whitelaw E: Epigenetics and phenotypic variation in mammals. Mamm Genome 2006, 17:365–374.CrossRefPubMed
16.
Klose RJ, Bird AP: Genomic DNA methylation: the mark and its mediators. Trends Biochem Sci 2006, 31:89–97.CrossRefPubMed
17.
Ball MP, Li JB, Gao Y, et al.: Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells. Nat Biotechnol 2009, 27:361–368.CrossRefPubMed
18.
Kao YH, Chen YC, Cheng CC, et al.: Tumor necrosis factor-alpha decreases sarcoplasmic reticulum Ca2+-ATPase expressions via the promoter methylation in cardiomyocytes. Crit Care Med 2010, 38:217–222.CrossRefPubMed
19.
• Movassagh M, Choy M-K, Goddard M, et al.: Differential DNA methylation correlates with differential expression of angiogenic factors in human heart failure. PLoS One 2010, 5:e8564. This study reports genome-wide evidence for differential methylation between CVD patients and controls.CrossRefPubMed
20.
Schroen B, Heymans S: MicroRNAs and beyond: the heart reveals its treasures. Hypertension 2009, 54:1189–1194.CrossRefPubMed
21.
• Silvestri P, Di Russo C, Rigattieri S, et al.: MicroRNAs and ischemic heart disease: towards a better comprehension of pathogenesis, new diagnostic tools and new therapeutic targets. Recent Pat Cardiovasc Drug Discov 2009, 4:109–118. This review offers a good compilation of evidence of miRNAs associated with HF.CrossRefPubMed
22.
Carè A, Catalucci D, Felicetti F, et al.: MicroRNA-133 controls cardiac hypertrophy. Nat Med 2007, 13:613–618.CrossRefPubMed
23.
Divakaran V, Mann DL: The emerging role of microRNAs in cardiac remodeling and heart failure. Circ Res 2008, 103:1072–1083.CrossRefPubMed
24.
van Rooij E, Sutherland LB, Qi X, et al.: Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 2007, 316:575–579.CrossRefPubMed
25.
Zhao Y, Ransom JF, Li A, et al.: Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell 2007, 129:303–317.CrossRefPubMed
26.
Thum T, Gross C, Fiedler J, et al.: MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008, 456:980–984.CrossRefPubMed
27.
Thum T, Galuppo P, Wolf C, et al.: MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation 2007, 116:258–267.CrossRefPubMed
28.
Zorio E, Medina P, Rueda J, et al.: Insights into the role of microRNAs in cardiac diseases: from biological signalling to therapeutic targets. Cardiovasc Hematol Agents Med Chem 2009, 7:82–90.CrossRefPubMed
29.
Huang TH, Perry MR, Laux DE: Methylation profiling of CpG islands in human breast cancer cells. Hum Mol Genet 1999, 8:459–470.CrossRefPubMed
30.
Kaneda R, Toyota M, Yamashita Y, et al.: High-throughput screening of genome fragments bound to differentially acetylated histones. Genes Cells 2004, 9:1167–1174.CrossRefPubMed
31.
Kaneda R, Ueno S, Yamashita Y, et al.: Genome-wide screening for target regions of histone deacetylases in cardiomyocytes. Circ Res 2005, 97:210–218.CrossRefPubMed
32.
Soifer HS, Rossi JJ, Saetrom P: MicroRNAs in disease and potential therapeutic applications. Mol Ther 2007, 15:2070–2079.CrossRefPubMed
33.
Feinberg AP: Phenotypic plasticity and the epigenetics of human disease. Nature 2007, 447:433–440.CrossRefPubMed
34.
Pucéat M: Pharmacological approaches to regenerative strategies for the treatment of cardiovascular diseases. Curr Opin Pharmacol 2008, 8:189–192.CrossRefPubMed
35.
Gomez A, Ingelman-Sundberg M: Pharmacoepigenetics: its role in interindividual differences in drug response. Clin Pharmacol Ther 2009, 85:226–230.CrossRef
36.
Bolden JE, Peart MJ, Johnstone RW: Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006, 5:769–784.CrossRefPubMed
37.
Gallo P, Latronico MV, Gallo P, et al.: Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure. Cardiovasc Res 2008, 80:416–424.CrossRefPubMed
38.
39.
Anway MD, Cupp AS, Uzumcu M, Skinner MK: Epigenetic transgenerational actions of endocrine disruptors and male fertility. Science 2005, 308:1466–1469.CrossRefPubMed
40.
Turan N, Katari S, Coutifaris C, Sapienza C: Explaining inter-individual variability in phenotype: is epigenetics up to the challenge? Epigenetics 2010, 5:16–19.CrossRefPubMed
41.
Fraga MF, Ballestar E, Paz MF, et al.: Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci USA 2005, 102:10604–10609.CrossRefPubMed
42.
The American Association for Cancer Research Human Epigenome Task Force and European Union, Network of Excellence, Scientific Advisory Board: Moving AHEAD with an international human epigenome project. Nature 2008, 454:711–715.CrossRef
43.
Mishra PK, Tyagi N, Kumar M, Tyagi SC: MicroRNAs as a therapeutic target for cardiovascular diseases. J Cell Mol Med 2009, 13:778–789.CrossRefPubMed
44.
Chen JF, Murchison EP, Tang R, et al.: Targeted deletion of Dicer in the heart leads to dilated cardiomyopathy and heart failure. Proc Natl Acad Sci U S A 2008, 105:2111–2116.CrossRefPubMed
45.
Kwon C, Han Z, Olson EN, Srivastava D: MicroRNA1 influences cardiac differentiation in Drosophila and regulates Notch signaling. Proc Natl Acad Sci U S A 2005, 102:18986–18991.CrossRefPubMed
46.
Zhao Y, Samal E, Srivastava D: Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature 2005, 436:214–220.CrossRefPubMed
47.
Chen JF, Mandel EM, Thomson JM, et al.: The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet 2006, 38:228–233.CrossRefPubMed
48.
Yang B, Lin H, Xiao J, et al.: The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat Med 2007, 13:486–491.CrossRefPubMed
49.
Terentyev D, Belevych AE, Terentyeva R, et al.: miR-1 overexpression enhances Ca2+ release and promotes cardiac arrhythmogenesis by targeting PP2A regulatory subunit B56{alpha} and causing CaMKII-dependent hyperphosphorylation of RyR2. Circ Res 2009, 104:514–521.CrossRefPubMed
50.
Luo X, Lin H, Pan Z, et al.: Down-regulation of miR-1/miR-133 contributes to re-expression of pacemaker channel genes HCN2 and HCN4 in hypertrophic heart. J Biol Chem 2008, 283:20045–20052.CrossRefPubMed
51.
Luo X, Xiao J, Lin H, et al.: Transcriptional activation by stimulating protein 1 and post-transcriptional repression by muscle-specific microRNAs of IKs-encoding genes and potential implications in regional heterogeneity of their expressions. J Cell Physiol 2007, 212:358–367.CrossRefPubMed
52.
Ikeda S, He A, Kong SW, et al.: microRNA-1 negatively regulates expression of the hypertrophy-associated genes calmodulin and Mef2a. Mol Cell Biol 2009, 29:2193–2204.CrossRefPubMed
53.
Sayed D, Hong C, Chen IY, et al.: MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ Res 2007, 100:416–424.CrossRefPubMed
54.
Xu C, Lu Y, Pan Z, et al.: The muscle-specific microRNAs miR-1 and miR-133 produce opposing effects on apoptosis by targeting HSP60, HSP70 and caspase-9 in cardiomyocytes. J Cell Sci 2007, 120:3045–3052.CrossRefPubMed
55.
Liu N, Bezprozvannaya S, Williams AH, et al.: microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes Dev 2008, 22:3242–3254.CrossRefPubMed
56.
Duisters RF, Tijsen AJ, Schroen B, et al.: miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ Res 2009, 104:170–178.CrossRefPubMed
57.
Xiao J, Luo X, Lin H, et al.: MicroRNA miR-133 represses HERG K+ channel expression contributing to QT prolongation in diabetic hearts. J Biol Chem 2007, 282:12363–12367.CrossRefPubMed
58.
Sucharov C, Bristow MR, Port JD: miRNA expression in the failing human heart: functional correlates. J Mol Cell Cardiol 2008, 45:185–192.CrossRefPubMed
Metadata
Title
Pharmacoepigenetics in Heart Failure
Authors
Irene Mateo Leach
Pim van der Harst
Rudolf A. de Boer
Publication date
01-06-2010
Publisher
Current Science Inc.
Published in
Current Heart Failure Reports / Issue 2/2010
Print ISSN: 1546-9530
Electronic ISSN: 1546-9549
DOI
https://doi.org/10.1007/s11897-010-0011-y

Other articles of this Issue 2/2010

Current Heart Failure Reports 2/2010 Go to the issue

ReviewPaper

Venous Congestion and Endothelial Cell Activation in Acute Decompensated Heart Failure

ReviewPaper

Testosterone Deficiency and Exercise Intolerance in Heart Failure: Treatment Implications

ReviewPaper

Electrical Muscle Stimulation for Chronic Heart Failure: An Alternative Tool for Exercise Training?

ReviewPaper

Relaxin: Review of Biology and Potential Role in Treating Heart Failure

Clinical Trial Report

Iron in Heart Failure: Friend or Foe?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits